PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
Read more
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
News & events
News
Press release
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
Read more
News
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
Read more
Press release
PHAXIAM Therapeutics announces 2023 Full-Year Results and Provides Business Update
Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET
Read morePress release
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
PHAXIAM today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective
Read morePress release
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Read more
News
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million).
Read morePress release
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Conference call and webcast (English) on Wednesday, November 15, 2023at 8:30am ET / 2:30pm CET
Read moreNews
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Read more
Press release
PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares
TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share
Read morePress release
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
Read more
Press release
PHAXIAM Receives Compliance Notice from Nasdaq
Read more